Pharmacogenomics and variations in the risk of toxicity during the consolidation/maintenance phases of the treatment of pediatric b-cell leukemia patients from an admixed population in the brazilian amazon

Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer, representing approximately 30% of all malignant pediatric neoplasia [1,2]. In about 85% of children with ALL, the leukemia starts in the B cells (B-cell ALL). Recent advances in the chemotherapy of childhood ALL, based on a cocktail of chemotherapeutic drugs that includes inhibitors of tyrosine kinases, have resulted in survival rates of>90% [3]. Despite the clinical success of this treatment, around 20% of the children present serious toxicological complications that require a reduction in the dosage or even the complete interruption of the treatment [4].

Source: Leukemia Research - September 15, 2018 Category: Hematology Authors: Darlen Cardoso de Carvalho, Alayde Vieira Wanderley, Andr é Mauricio Ribeiro dos Santos, Marianne Rodrigues Fernandes, Amanda de Nazaré Cohen Lima de Castro, Luciana Pereira Colares Leitão, João Augusto Nunes de Carvalho Junior, Tatiane Piedade de Sou Source Type: research